Skip to main content

Cellectar Biosciences, Inc.

CLRB
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001279704

No open-market purchases or sales by Cellectar Biosciences, Inc. insiders were filed in the last 90 days; 29 institutions reported holding it in 13F filings for Q2 2026, worth $9.08M in total; no superinvestor holds it.

Q4 2022 vs. Q3 2022

How the institutions holding Cellectar Biosciences, Inc. changed between Q3 2022 and Q4 2022.

All holders in Q4 2022All holders in Q3 2022

13F holders of CLRB: Q3 2022 compared with Q4 2022
MeasureQ3 2022Of which not filed for Q4 2022Q4 2022Change
Holders22126+5
Shares636.5K21.8K1.90M+1.29M (+209.2%)
Value$2.14M$73.0K$3.22M+$1.15M (+55.6%)

1 institution that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so the changes leave them out.

New holders (7)

Institutions that held Cellectar Biosciences, Inc. at the end of Q4 2022 but not at the end of Q3 2022.

Institutions new to CLRB in Q4 2022
InstitutionSharesValue% of portfolio
CVI Holdings, LLC166,049$283.9K0.04%
Citadel Advisors LLC18,670$31.9K0.00%
MinichMacGregor Wealth Management, LLC140$2390.00%
Harbour Investments, Inc.40$680.00%
Bank of America Corp20$340.00%
Altshuler Shaham Ltd20,000$00.00%
Transamerica Financial Advisors, Inc.5––

Sold out (2)

Institutions that held Cellectar Biosciences, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.

Institutions that sold out of CLRB in Q4 2022
InstitutionShares, Q3 2022Value, Q3 2022
Difesa Capital Management, LP10,000$34.0K
IFP Advisors, Inc5$1.00K

Not filed for Q4 2022 yet (1)

Institutions that held Cellectar Biosciences, Inc. at the end of Q3 2022 and haven't filed a 13F for Q4 2022. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding CLRB in Q3 2022 that haven't filed for Q4 2022
InstitutionShares, Q3 2022Value, Q3 2022
ACT Capital Management, LLC21,750$73.0K